A suspension order from regulators
According to the documents, the Central Drugs Standard Control Organisation (CDSCO) and the office of the Drugs Controller of Assam ordered the shutdown on August 20, after a joint inspection found lapses in the system meant to ensure product quality and safety. Earlier, on August 10, the regulators issued a show-cause notice; dissatisfied with the company’s response, they ordered a halt to all ophthalmic activity at the plant.
Sun Pharma will be unable to resume eye-care production there until it submits a satisfactory compliance report. An official said the company has submitted a report, which regulators are reviewing. Sun Pharma had expected the site to become one of its largest manufacturing hubs for sterile products.
332 batches recalled
Regulators sought more information on the recall of 332 batches of ophthalmic suspensions, liquids used to treat eye conditions. In an internal notice to stockists, the company described the recall as a “precautionary measure.”

















